How do I calculate and interpret the Canadian Syncope Risk Score (CSRS) for risk stratifying a patient with syncope?

Canadian Syncope Risk Score (CSRS) Calculation and Interpretation

The Canadian Syncope Risk Score is a validated 9-variable clinical decision tool that accurately predicts 30-day serious adverse events in ED syncope patients, with excellent discrimination (AUROC 0.87-0.91) and should be used to guide disposition decisions. 12

How to Calculate the CSRS

The CSRS assigns points based on 9 clinical variables identified during the initial ED evaluation:

Clinical Predictors (from derivation study):

1. Predisposition to vasovagal syncope (protective factor - negative points)
2. Heart disease (structural or ischemic)
3. Systolic blood pressure <90 or >180 mm Hg (any reading in ED)
4. Troponin level above 99th percentile
5. Abnormal QRS axis (<-30° or >100°)
6. QRS duration >130 ms
7. QTc interval >480 ms
8. ED diagnosis of cardiac syncope
9. ED diagnosis of vasovagal syncope (protective factor - negative points)

1

Score Interpretation and Risk Stratification

Risk Categories and 30-Day Serious Adverse Event Rates:

• Very Low Risk (CSRS <-2): 0.3-0.4% risk
• Low Risk (CSRS -1 to 0): ~1% risk
• Medium Risk (CSRS 1-3): 3-8% risk
• High Risk (CSRS 4-5): 15-20% risk
• Very High Risk (CSRS ≥6): >50% risk

12

Clinical Decision Thresholds

At a threshold score of -1 or higher:

• Sensitivity: 97.7-97.8%
• Specificity: 44.3%
• Negative predictive value: 97-99%

This means patients with CSRS <0 can be safely discharged, as their risk of serious adverse events is <1%. 23

Disposition Algorithm:

• CSRS <0: Safe for discharge with outpatient follow-up
• CSRS 0-3: Consider brief ED observation or admission based on clinical context
• CSRS ≥4: Hospitalization recommended for further evaluation

24

What Constitutes "Serious Adverse Events"

The CSRS predicts these 30-day outcomes:

• Death
• Myocardial infarction
• Arrhythmia (ventricular tachycardia/fibrillation, complete heart block, symptomatic bradycardia/supraventricular tachycardia requiring intervention)
• Structural heart disease (aortic stenosis, pulmonary hypertension, cardiac tamponade, hypertrophic cardiomyopathy)
• Pulmonary embolism
• Serious hemorrhage
• Procedural interventions (pacemaker, ICD, cardiac surgery, endoscopy for bleeding)

12

Evidence Quality and Validation

The CSRS has been validated in multiple international cohorts with consistent performance:

• Original Canadian validation (2020): 3,819 patients, AUROC 0.91, with excellent calibration 2
• US validation (2026): 1,263 patients, AUROC 0.72, sensitivity 91.9% at low-risk threshold 5
• Turkish validation (2023): Superior to SFSR and OESIL scores for predicting mortality (AUROC 0.869) 3
• Italian validation (2026): Modified version without ED diagnosis variable maintained AUROC 0.87 6

The 2017 ACC/AHA/HRS Syncope Guidelines acknowledge that "use of risk stratification scores may be reasonable in the management of patients with syncope" (Class IIb, LOE B-NR), though they note limitations in existing scores 7. The CSRS was developed after these guidelines and represents the most rigorously validated tool currently available.

Practical Implementation Considerations

Key advantages:

• All variables obtainable during routine ED evaluation
• No requirement for prolonged observation or specialized testing
• Validated across diverse healthcare settings and populations

Common pitfalls to avoid:

• Don't use CSRS if a serious diagnosis is already identified during initial ED evaluation (e.g., acute MI, PE, dissection) - these patients require admission regardless of score
• Ensure troponin is measured (not just ordered) before calculating score
• QRS axis and intervals must be measured from ECG - don't estimate
• The "ED diagnosis" variables require clinical judgment but should be based on history/exam findings, not the score itself (to avoid circular reasoning)

12

Clinical impact: Studies suggest that implementing CSRS could reduce unnecessary hospitalizations by approximately 39%, as many currently admitted patients have low-risk scores (<1) with estimated 30-day serious adverse event rates under 1% 4.

The CSRS outperforms unstructured physician judgment, particularly for identifying truly low-risk patients who can be safely discharged 25.